Thermo Fisher Scientific
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Lab-tools and bioprocessing razor-blade with FDA-validated workflows that make switching prohibitively expensive in regulated pharma manufacturing.
Thermo Fisher's moat is the regulatory cost of switching — once a TMO instrument is validated for cGMP production, swapping it requires re-running the full regulatory submission:
- FDA-Validated Switching Cost: When a pharma customer validates a TMO instrument or reagent for cGMP production, replacing it requires full process revalidation — months of work, $millions in cost, and tapeout-equivalent regulatory risk. This is the dominant moat for the bioproduction segment.
- Razor-Blade Economics: TMO sells the instrument once, then captures recurring consumables, reagents, and service revenue at high margins for the instrument's 8-15 year life. Roughly 80% of revenue is recurring consumables/service — the installed base compounds even when capex slows.
- M&A Compounding Engine: TMO has a 30-year track record of acquiring scientific tooling companies (Life Tech, Patheon, PPD, Thermo Electron, Olink, Clario) and bolting them onto the global commercial channel. The bolt-on model adds 2-3pp of growth above organic in most years.
Moat Verdict
Thermo Fisher is a moderate AI beneficiary. The strongest moats — regulatory lock-in, transaction embedding, and the bundling razor-blade — are AI-neutral or AI-strengthened (AI assists method development without disrupting the regulatory cost-of-switching). The AI-vulnerable categories (learnedInterfaces, businessLogic, talentScarcity) are merely intact rather than destroyed because regulated workflows protect them. Sits in the healthcare peer range (80-90) alongside ISRG/LLY, just below the financial-data oligopoly tier.
65.0 resilient · 74.5 vulnerable · 80/20 = 66.9 · = 67
Open a moat to read its note.
Lab scientists train on Thermo Scientific platforms (Orbitrap mass spec, Vanquish HPLC) and Pierce reagents over years. Methods libraries embedded in customer SOPs. AI is starting to abstract some operations but the regulatory validation layer keeps interface mastery sticky.
Customer SOPs and validated workflows are encoded against specific TMO instruments and reagent SKUs. Switching forces re-validation. Strong but not deeply customized like enterprise software.
lab tools business does not derive moat from public datasets.
Field application scientists who deploy TMO instruments at biotech customers are scarce, but not as differentiating as Cadence FAEs because the workflows are more standardized.
Instruments + reagents + consumables + service + clinical trial software (Clario) — the cross-sell engine drives 5-7% of organic growth annually. Competitors (Danaher, Agilent) have narrower bundles in any single segment.
Installed-base service contracts and customer-specific validated method libraries. Real but the data is customer-owned, not TMO-exclusive.
Once a customer validates a Thermo Fisher instrument into a cGMP, EU GMP or pharmacopeia workflow, replacing it means months of costly revalidation. Danaher, Agilent and Waters instruments are validated the same way, so the approvals are table stakes and rate intact.
Scale buying through one-stop-shop channel; broad portfolio attracts large pharma master service agreements. Indirect network effects via reagent ecosystem partners.
Reagents, consumables and service contracts are reordered weekly by research labs and biopharma plants. The cross-sell that ties them together is already rated strong under bundling, and no retention figure is on file for the consumables alone, so it rates intact (one fact, one pillar).
Sample tracking, QC data, and method libraries for many customers run on TMO software (SampleManager LIMS, Chromeleon, Clario eCOA). Not the SoR for the science itself but a SoR for compliance data.
The Fisher channel is the largest life-science distribution network, lowering cost to serve labs, but Danaher and Avantor compete at scale.
Buyers are enterprises choosing on switching cost, integration and performance, which the other pillars rate. The name carries reputation, not a price premium it could hold on brand alone.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Lab-tools and bioprocessing razor-blade with FDA-validated workflows that make switching prohibitively expensive in regulated pharma manufacturing.
Growth Score
Q2 2026 showed a cleaner recovery than Q1: revenue grew 10% to $11.99B, organic revenue grew 5% (Q1: revenue +6% to $11.01B, organic +1%), adjusted EPS rose 13% to $6.03, and adjusted operating margin expanded 90 bps to 22.8% after slipping 10 bps to 21.8% in Q1. Management raised FY26 guidance to $47.4-48.1B revenue — +6-8% on FY2025's $44.56B, including acquired revenue — and $24.93-25.33 adjusted EPS, while now expecting organic growth at the upper end of the 3-4% range. The pending microbiology divestiture trims 2026 revenue by about $200M and adjusted EPS by $0.05, so the guidance raise is higher quality than the headline suggests.
Valuation Score
At $603.01, TMO is now much closer to fair value: about 89% of the way from the rebuilt bear case ($470) to base case ($620). Q2 supports lifting the ladder because organic growth improved to 5%, margin expanded, and FY26 EPS guidance moved up despite the microbiology divestiture. The valuation score falls because the stock moved faster than the guide: upside now requires sustained 4%+ organic growth and bioprocessing recovery, not just a return to normal from the 2025 trough.
The FDA-Validated Workflow Moat
Thermo Fisher's moat is the regulatory cost of switching — once a TMO instrument is validated for cGMP production, swapping it requires re-running the full regulatory submission:
- FDA-Validated Switching Cost: When a pharma customer validates a TMO instrument or reagent for cGMP production, replacing it requires full process revalidation — months of work, $millions in cost, and tapeout-equivalent regulatory risk. This is the dominant moat for the bioproduction segment.
- Razor-Blade Economics: TMO sells the instrument once, then captures recurring consumables, reagents, and service revenue at high margins for the instrument's 8-15 year life. Roughly 80% of revenue is recurring consumables/service — the installed base compounds even when capex slows.
- M&A Compounding Engine: TMO has a 30-year track record of acquiring scientific tooling companies (Life Tech, Patheon, PPD, Thermo Electron, Olink, Clario) and bolting them onto the global commercial channel. The bolt-on model adds 2-3pp of growth above organic in most years.
Moat Verdict
Thermo Fisher is a moderate AI beneficiary. The strongest moats — regulatory lock-in, transaction embedding, and the bundling razor-blade — are AI-neutral or AI-strengthened (AI assists method development without disrupting the regulatory cost-of-switching). The AI-vulnerable categories (learnedInterfaces, businessLogic, talentScarcity) are merely intact rather than destroyed because regulated workflows protect them. Sits in the healthcare peer range (80-90) alongside ISRG/LLY, just below the financial-data oligopoly tier.
65.0 resilient · 74.5 vulnerable · 80/20 = 66.9 · = 67
Open a moat to read its note.
Lab scientists train on Thermo Scientific platforms (Orbitrap mass spec, Vanquish HPLC) and Pierce reagents over years. Methods libraries embedded in customer SOPs. AI is starting to abstract some operations but the regulatory validation layer keeps interface mastery sticky.
Customer SOPs and validated workflows are encoded against specific TMO instruments and reagent SKUs. Switching forces re-validation. Strong but not deeply customized like enterprise software.
lab tools business does not derive moat from public datasets.
Field application scientists who deploy TMO instruments at biotech customers are scarce, but not as differentiating as Cadence FAEs because the workflows are more standardized.
Instruments + reagents + consumables + service + clinical trial software (Clario) — the cross-sell engine drives 5-7% of organic growth annually. Competitors (Danaher, Agilent) have narrower bundles in any single segment.
Installed-base service contracts and customer-specific validated method libraries. Real but the data is customer-owned, not TMO-exclusive.
Once a customer validates a Thermo Fisher instrument into a cGMP, EU GMP or pharmacopeia workflow, replacing it means months of costly revalidation. Danaher, Agilent and Waters instruments are validated the same way, so the approvals are table stakes and rate intact.
Scale buying through one-stop-shop channel; broad portfolio attracts large pharma master service agreements. Indirect network effects via reagent ecosystem partners.
Reagents, consumables and service contracts are reordered weekly by research labs and biopharma plants. The cross-sell that ties them together is already rated strong under bundling, and no retention figure is on file for the consumables alone, so it rates intact (one fact, one pillar).
Sample tracking, QC data, and method libraries for many customers run on TMO software (SampleManager LIMS, Chromeleon, Clario eCOA). Not the SoR for the science itself but a SoR for compliance data.
The Fisher channel is the largest life-science distribution network, lowering cost to serve labs, but Danaher and Avantor compete at scale.
Buyers are enterprises choosing on switching cost, integration and performance, which the other pillars rate. The name carries reputation, not a price premium it could hold on brand alone.
Growth Analysis
Growth Drivers
Key Risk
If pharma/biotech bioproduction demand rolls over again in 2H 2026 and organic growth falls back below 3% after the Q2 acceleration, the raised EPS guide becomes dependent on cost actions and M&A rather than the core recurring-revenue engine.
Score Derivation
66.3 base + 2.7 trajectory + 4 margin − 5 risk = 68
Base 66.3 (5-8% revenue CAGR, midpoint 6.5%) + 2.7 trajectory (Life Sciences Solutions and Lab Products & Biopharma Services accelerating as organic growth went +1% → +5%; Clario bolt-on stable) + 4 expanding margin (adjusted operating margin 21.8% in Q1, −10bps, then 22.8% in Q2, +90bps) − 5 moderate pharma/biotech funding risk = 68
Price Scenarios (12–24 Months)
Valuation Multiples
| Trailing P/E (GAAP) | ~25× |
| Forward P/E (NTM) | ~24× |
| PEG Ratio | ~2.7× |
| Price / Sales (NTM) | ~4.7× |
| Price / FCF | ~30× |
Forward P/E has re-rated from a discount to roughly the middle of the healthcare-tools quality range. That is justified by Q2's 5% organic growth and 22.8% adjusted margin, but the easy valuation gap has closed. The microbiology divestiture sharpens the portfolio but is modestly dilutive, so the next leg depends on recurring consumables and bioprocessing demand staying firm.
Approximate figures as of August 2026.
Where We Are vs Targets
Loading live price…
Bioprocessing recovery stalls into 2027, Q2 organic strength proves temporary, tariff and funding headwinds return, and the multiple compresses toward 18-19× forward earnings.
- Pharma/biotech capex remains soft, and organic growth falls back below 3% after the Q2 2026 acceleration
- Tariff, FX, and microbiology separation costs offset productivity, pulling adjusted operating margin back toward 21.5%
- Forward P/E re-rates to ~18-19× on a $25 EPS base as the slow-organic narrative becomes structural
FY26 guide hits the raised midpoint ($47.75B revenue / $25.13 EPS), organic growth holds near 4% in 2H, and the multiple holds around 24-25× forward earnings.
- Organic growth remains near the upper end of the 3-4% FY guide after Q2's 5% print, confirming that customer activity has strengthened
- Clario integration contributes to 2027 EPS while the microbiology divestiture is absorbed without disrupting channel relationships
- Adjusted operating margin stays above 22.5% as productivity offsets tariffs, FX, and divestiture dilution
Bioprocessing fully recovers to sustained mid-single-digit organic growth, M&A returns to accretive bolt-ons, and the multiple expands toward TMO's premium historical range.
- GLP-1 manufacturing capacity buildouts and biologics pipeline drive bioproduction back to high-single-digit organic growth
- Accretive M&A resumes in clinical trials, diagnostics, or specialty consumables after the microbiology divestiture closes
- Forward P/E re-rates to 27-28× as the compounder narrative reasserts and 2027 EPS power approaches $28